Status:
RECRUITING
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
Lead Sponsor:
RenJi Hospital
Conditions:
Breast Cancer
Circulating Tumor Cell
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cel...
Eligibility Criteria
Inclusion
- Female, aged ≥18 and ≤70 years;
- Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
- Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
- Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
- ECOG 0-1
Exclusion
- Metastatic disease (Stage IV);
- Female patients who are pregnancy or lactation;
- Uncontrollable puncture site infection or systemic infection;
Key Trial Info
Start Date :
September 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2029
Estimated Enrollment :
484 Patients enrolled
Trial Details
Trial ID
NCT05360290
Start Date
September 14 2022
End Date
June 1 2029
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127